According to Hong Kong China Review News Agency, Taiwan’s “high-end” vaccine obtained an emergency user license (EUA) yesterday, but since the Ministry of Health and Welfare announced the EUA review standards for Taiwan-made vaccines on June 10, related disputes have been continuously made. The biggest key is that the review meeting is insufficient transparency. Who are the review committee members? The relevant units have always kept it confidential, and the review meeting has not been recorded, so the credibility of the meeting results is of course arousing doubts. No wonder even experts do not believe in the beautiful data released by the Food and Drug Administration.
Taiwan's Food and Drug Administration originally planned to hold an expert meeting next week to review the "high-end" vaccine, but the results were suddenly announced yesterday. Although the results were not surprising, they did not record the entire process and lacked credibility. Taking the United States as an example, when reviewing the EUA qualifications of Pfizer BNT and Moderna vaccines, not only can the full length of more than 8 hours be watched through live broadcasts on the Internet, but even the media and the public can see the discussion and voting process.
According to the analysis and report of "China Times News Network", reviewing "high-end" vaccines is not only closed-door meetings, but also without video recording throughout the whole process. The "Food and Drug Administration" was unwilling to disclose the identity of the expert group member. Even the reasons why the experts expressed disagreement and what supplements were required, Taiwan's "Food and Drug Administration" Wu Xiumei said she had nothing to know.
The "high-end" vaccine is the world's first COVID-19 vaccine to obtain EUA through immunity bridging. Not only does the public in Taiwan care about it, but the international community will also be concerned. However, the "FDA" requires high-end vaccines to provide safety monitoring reports every month during the project approval and manufacturing period, and to be inspected and sent to domestic and overseas for the implementation of vaccine protection benefits within one year after approval. The implication is that "high-end" vaccines must analyze the protection power of their own vaccines in the real world within one year.
In other words, people who receive "high-end" vaccines within the next year are likely to become the targets of disguised phase 3 clinical trials. Before the attack, there is no idea how much protection is, and there is a risk of infection. "High-end" was originally a "placement vaccine" and could be added to public vaccination as early as August. Although Taiwan's "epidemic command center" has not yet explained how to use it, under the current circumstances, young people who cannot get international vaccines now may not be able to escape the fate of being a "white rat" in the future. (Source: China Review News Agency)
